Foster & Motley Inc. Has $1.60 Million Stock Position in Cabot Co. (NYSE:CBT)

Foster & Motley Inc. trimmed its position in Cabot Co. (NYSE:CBT) by 0.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 14,315 shares of the specialty chemicals company’s stock after selling 133 shares during the quarter. Foster & Motley Inc.’s holdings in Cabot were worth $1,600,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Van ECK Associates Corp boosted its holdings in shares of Cabot by 40.0% in the third quarter. Van ECK Associates Corp now owns 31,549 shares of the specialty chemicals company’s stock worth $3,445,000 after buying an additional 9,014 shares during the period. Harbor Capital Advisors Inc. grew its position in Cabot by 48.0% during the third quarter. Harbor Capital Advisors Inc. now owns 33,444 shares of the specialty chemicals company’s stock valued at $3,738,000 after purchasing an additional 10,852 shares in the last quarter. Farther Finance Advisors LLC grew its position in Cabot by 197.9% during the third quarter. Farther Finance Advisors LLC now owns 417 shares of the specialty chemicals company’s stock valued at $47,000 after purchasing an additional 277 shares in the last quarter. New York State Common Retirement Fund grew its position in Cabot by 16.1% during the third quarter. New York State Common Retirement Fund now owns 259,378 shares of the specialty chemicals company’s stock valued at $28,991,000 after purchasing an additional 36,036 shares in the last quarter. Finally, US Bancorp DE grew its position in Cabot by 0.9% during the third quarter. US Bancorp DE now owns 30,485 shares of the specialty chemicals company’s stock valued at $3,407,000 after purchasing an additional 267 shares in the last quarter. 93.18% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on CBT shares. Mizuho boosted their price objective on shares of Cabot from $103.00 to $122.00 and gave the company an “outperform” rating in a research report on Tuesday. UBS Group lowered their price objective on shares of Cabot from $103.00 to $98.00 and set a “neutral” rating on the stock in a research report on Tuesday, August 6th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Cabot from $95.00 to $105.00 and gave the company a “neutral” rating in a research report on Wednesday, August 7th. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $105.00.

Insiders Place Their Bets

In other news, CEO Sean D. Keohane sold 25,617 shares of the business’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $101.55, for a total value of $2,601,406.35. Following the completion of the sale, the chief executive officer now directly owns 331,174 shares in the company, valued at approximately $33,630,719.70. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, EVP Hobart Kalkstein sold 5,457 shares of the business’s stock in a transaction on Tuesday, August 20th. The shares were sold at an average price of $100.58, for a total value of $548,865.06. Following the completion of the sale, the executive vice president now directly owns 61,688 shares in the company, valued at approximately $6,204,579.04. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Sean D. Keohane sold 25,617 shares of the business’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $101.55, for a total transaction of $2,601,406.35. Following the completion of the sale, the chief executive officer now owns 331,174 shares of the company’s stock, valued at $33,630,719.70. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 48,665 shares of company stock valued at $4,986,299 over the last ninety days. Corporate insiders own 3.07% of the company’s stock.

Cabot Stock Performance

CBT stock opened at $117.02 on Thursday. The company has a quick ratio of 1.45, a current ratio of 2.22 and a debt-to-equity ratio of 0.72. The company has a market capitalization of $6.42 billion, a price-to-earnings ratio of 17.36, a P/E/G ratio of 0.91 and a beta of 1.20. Cabot Co. has a 12 month low of $68.11 and a 12 month high of $117.37. The firm has a 50 day moving average of $108.69 and a two-hundred day moving average of $101.24.

Cabot (NYSE:CBT) last posted its earnings results on Monday, November 4th. The specialty chemicals company reported $1.80 EPS for the quarter, missing the consensus estimate of $1.81 by ($0.01). The business had revenue of $1 billion during the quarter, compared to the consensus estimate of $1.01 billion. Cabot had a return on equity of 26.99% and a net margin of 12.05%. The business’s revenue was up 3.7% on a year-over-year basis. During the same period in the prior year, the firm earned $1.65 earnings per share. As a group, equities analysts anticipate that Cabot Co. will post 7.07 EPS for the current fiscal year.

Cabot Profile

Cabot Corporation operates as a specialty chemicals and performance materials company. The company operates through two segments, Reinforcement Materials and Performance Chemicals. It offers reinforcing carbons that are used in tires as a rubber reinforcing agent and performance additive, as well as in industrial products, such as hoses, belts, extruded profiles, and molded goods; and engineered elastomer composites solutions.